bioMérieux S.A. (BMXMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
bioMérieux S.A. (BMXMF) with AI Score 52/100 (Hold). bioMérieux S. A. is a global leader in in vitro diagnostics, focusing on infectious disease diagnosis and microbiological testing. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026bioMérieux S.A. (BMXMF) Healthcare & Pipeline Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for infectious diseases, cardiovascular pathologies, and cancers. Serving clinical and industrial sectors globally, the company leverages its diagnostic systems and microbiological testing capabilities. As a subsidiary of Institut Mérieux SA, bioMérieux focuses on advancing healthcare through innovative diagnostic solutions.
Investment Thesis
bioMérieux S.A. presents a compelling investment case based on its leading position in the in vitro diagnostics market and its focus on infectious disease diagnosis. With a market capitalization of $14.19 billion and a healthy profit margin of 9.8%, the company demonstrates financial stability. Key growth catalysts include increasing demand for diagnostic solutions in emerging markets and continued innovation in its product offerings. The company's strong gross margin of 56.7% and return on equity of 9.5% further support its value proposition. However, investors may want to evaluate the company's debt-to-equity ratio of 11.24% and the competitive landscape within the diagnostics industry. The absence of a dividend yield may also influence investment decisions.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $14.19 billion, reflecting its significant presence in the in vitro diagnostics market.
- Profit margin of 9.8%, indicating efficient profitability in its operations.
- Gross margin of 56.7%, showcasing strong pricing power and cost management.
- Return on Equity (ROE) of 9.5%, demonstrating effective utilization of shareholder equity.
- Debt-to-Equity ratio of 11.24%, indicating a moderate level of financial leverage.
Competitors & Peers
Strengths
- Strong market position in in vitro diagnostics.
- Diverse product portfolio.
- Global presence.
- Established customer relationships.
Weaknesses
- Dependence on regulatory approvals.
- Exposure to currency fluctuations.
- Competition from larger players.
- Limited dividend yield.
Catalysts
- Upcoming: Potential for increased demand for diagnostic solutions due to emerging infectious disease outbreaks.
- Ongoing: Continued innovation in molecular diagnostics and personalized medicine.
- Ongoing: Expansion of product portfolio through strategic acquisitions.
- Ongoing: Growth in emerging markets with increasing healthcare expenditure.
- Upcoming: Potential regulatory approvals for new diagnostic platforms.
Risks
- Potential: Intense competition from larger players in the diagnostics industry.
- Potential: Dependence on regulatory approvals for new products.
- Ongoing: Exposure to currency fluctuations.
- Potential: Technological obsolescence.
- Ongoing: Economic downturns affecting healthcare spending.
Growth Opportunities
- Expansion in Emerging Markets: bioMérieux can leverage the increasing healthcare expenditure in emerging markets such as China and India. These regions face a growing burden of infectious diseases and require advanced diagnostic solutions. By establishing strategic partnerships and expanding its distribution network, bioMérieux can capture a significant share of these markets. The emerging markets diagnostics market is projected to grow at a CAGR of 8-10% over the next five years.
- Innovation in Molecular Diagnostics: Investing in research and development to create innovative molecular diagnostic solutions can drive growth. Molecular diagnostics offer rapid and accurate detection of infectious diseases, genetic disorders, and cancers. bioMérieux can focus on developing new assays and platforms for personalized medicine, catering to the growing demand for targeted therapies. The global molecular diagnostics market is expected to reach $15 billion by 2028.
- Strategic Acquisitions: Pursuing strategic acquisitions of smaller diagnostic companies with complementary technologies can enhance bioMérieux's product portfolio and market reach. Acquisitions can provide access to new markets, innovative technologies, and specialized expertise. By integrating acquired companies effectively, bioMérieux can strengthen its competitive position and accelerate growth. The diagnostics industry is ripe for consolidation, offering numerous acquisition opportunities.
- Development of Point-of-Care Testing Solutions: Focusing on the development and commercialization of point-of-care testing (POCT) solutions can address the growing demand for rapid and convenient diagnostics. POCT devices enable testing at or near the patient's location, reducing turnaround time and improving patient outcomes. bioMérieux can develop POCT solutions for infectious diseases, cardiac markers, and other critical parameters. The global POCT market is projected to reach $40 billion by 2027.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop companion diagnostics can drive growth and enhance bioMérieux's value proposition. Companion diagnostics are used to identify patients who are most likely to benefit from a specific drug, enabling personalized treatment strategies. By partnering with pharmaceutical companies, bioMérieux can gain access to new markets and generate revenue from companion diagnostic assays. The companion diagnostics market is expected to grow significantly in the coming years, driven by the increasing adoption of targeted therapies.
Opportunities
- Expansion in emerging markets.
- Development of innovative diagnostic solutions.
- Strategic acquisitions.
- Partnerships with pharmaceutical companies.
Threats
- Intense competition.
- Technological obsolescence.
- Economic downturns.
- Changes in healthcare regulations.
Competitive Advantages
- Strong brand reputation in the diagnostics industry.
- Extensive product portfolio covering various diagnostic areas.
- Global presence with operations in multiple countries.
- Established relationships with key customers in the healthcare sector.
About BMXMF
Founded in 1963 and headquartered in Marcy l'Etoile, France, bioMérieux S.A. has evolved into a global leader in the field of in vitro diagnostics. Originally known as B-D Mérieux, the company develops and produces diagnostic solutions aimed at identifying infectious diseases, cardiovascular pathologies, and various cancers. These solutions are crucial for clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. bioMérieux's offerings include diagnostic systems that analyze biological samples, as well as microbiological testing services primarily for the food, pharmaceutical, cosmetics, and veterinary sectors. The company's geographic reach spans the Americas, Europe, the Middle East, Africa, and the Asia Pacific, reflecting its commitment to global healthcare improvement. As a subsidiary of Institut Mérieux SA, bioMérieux continues to innovate and expand its diagnostic capabilities, addressing critical healthcare needs worldwide.
What They Do
- Develops in vitro diagnostic solutions for infectious diseases.
- Produces diagnostic systems for cardiovascular pathologies.
- Offers diagnostic solutions for various cancers.
- Provides microbiological testing for the food industry.
- Offers microbiological testing for the pharmaceutical sector.
- Provides microbiological testing for the cosmetics industry.
- Offers microbiological testing for the veterinary sector.
Business Model
- Develops and manufactures in vitro diagnostic systems.
- Sells diagnostic reagents and consumables.
- Provides microbiological testing services.
- Generates revenue through direct sales and distribution networks.
Industry Context
bioMérieux S.A. operates within the growing in vitro diagnostics market, driven by increasing healthcare expenditure and the rising prevalence of infectious diseases. The industry is characterized by technological advancements, stringent regulatory requirements, and intense competition. Key players focus on developing innovative diagnostic solutions for personalized medicine and point-of-care testing. The global in vitro diagnostics market is projected to reach billions of dollars in the coming years, fueled by aging populations and the need for early disease detection. bioMérieux's established presence and diverse product portfolio position it well to capitalize on these trends.
Key Customers
- Clinical and hospital laboratories.
- Physicians.
- Blood banks.
- Industrial control laboratories.
Financials
Chart & Info
bioMérieux S.A. (BMXMF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 4, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMXMF.
Price Targets
Wall Street price target analysis for BMXMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BMXMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Pierre Boulud
CEO
Pierre Boulud serves as the CEO of bioMérieux S.A., leading a global workforce of over 14,000 employees. His career spans several decades in the healthcare and diagnostics industries. Prior to joining bioMérieux, Boulud held various leadership positions at leading pharmaceutical and medical device companies. He brings extensive experience in strategic planning, operational management, and business development. Boulud's expertise lies in driving innovation and expanding market presence in the healthcare sector.
Track Record: Under Pierre Boulud's leadership, bioMérieux S.A. has focused on expanding its global footprint and investing in innovative diagnostic solutions. Key achievements include the successful launch of new diagnostic platforms and the expansion of the company's presence in emerging markets. Boulud has also overseen strategic acquisitions and partnerships to enhance bioMérieux's product portfolio and market reach. His focus on innovation and operational excellence has contributed to the company's growth and profitability.
BMXMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that bioMérieux S.A. (BMXMF) may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BMXMF.
- Low trading volume can lead to price volatility and difficulty in exiting positions.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- Lack of regulatory oversight may expose investors to greater risks.
- The company may not meet the listing requirements of higher-tier exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- bioMérieux S.A. is a subsidiary of Institut Mérieux SA, a reputable holding company.
- The company has a long operating history, founded in 1963.
- bioMérieux S.A. has a global presence and serves various sectors.
- The company develops and produces in vitro diagnostic solutions.
- The company has over 14,000 employees.
BMXMF Healthcare Stock FAQ
What does bioMérieux S.A. do?
bioMérieux S.A. specializes in the development, manufacture, and marketing of in vitro diagnostic solutions. These solutions are used to diagnose infectious diseases, cardiovascular pathologies, and various cancers. The company serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. Its products include diagnostic systems that analyze biological samples and microbiological testing services for the food, pharmaceutical, cosmetics, and veterinary sectors. bioMérieux's focus is on improving patient health and safety through innovative diagnostic solutions.
What do analysts say about BMXMF stock?
Analyst coverage of BMXMF is limited due to its OTC listing. However, considering bioMérieux S.A.'s financial performance and market position, analysts generally view the company as a stable player in the in vitro diagnostics market. Key valuation metrics include its market capitalization of $14.19 billion, profit margin of 9.8%, and gross margin of 56.7%. Growth considerations include the company's expansion in emerging markets and its focus on innovative diagnostic solutions. Investors should conduct their own due diligence and consider their risk tolerance before investing.
What are the main risks for BMXMF?
The main risks for BMXMF include intense competition from larger players in the diagnostics industry, dependence on regulatory approvals for new products, and exposure to currency fluctuations. Technological obsolescence and economic downturns can also affect the company's performance. As an OTC-listed stock, BMXMF carries additional risks related to limited financial disclosure and low trading volume. Investors should carefully consider these risks and conduct thorough due diligence before investing in BMXMF.
What are the key factors to evaluate for BMXMF?
bioMérieux S.A. (BMXMF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Strong market position in in vitro diagnostics.. Primary risk to monitor: Potential: Intense competition from larger players in the diagnostics industry.. This is not financial advice.
How frequently does BMXMF data refresh on this page?
BMXMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BMXMF's recent stock price performance?
Recent price movement in bioMérieux S.A. (BMXMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in in vitro diagnostics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BMXMF overvalued or undervalued right now?
Determining whether bioMérieux S.A. (BMXMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BMXMF?
Before investing in bioMérieux S.A. (BMXMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.